Comprehensive Clinical Guide: Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy (HOCM)

Hypertrophic Obstructive Cardiomyopathy (HOCM) represents a complex, genetically driven structural heart disease characterized by the thickening of the heart muscle, specifically the interventricular septum. When this thickening results in the obstruction of blood flow from the left ventricle into the aorta, it is classified as "obstructive." Septal Myectomy remains the gold-standard surgical intervention for symptomatic patients who have failed to respond to optimized pharmacological therapy. This guide serves as an authoritative resource for clinical practitioners, surgical teams, and informed patients.

1. Introduction and Clinical Overview

Septal Myectomy, often referred to as the Morrow procedure, is an open-heart surgical intervention designed to alleviate left ventricular outflow tract (LVOT) obstruction. By surgically excising a portion of the hypertrophied interventricular septum, the surgeon widens the outflow tract, thereby reducing the pressure gradient that impedes cardiac output and causes debilitating symptoms such as dyspnea, syncope, and angina.

While modern advancements in catheter-based therapies exist, surgical myectomy remains the benchmark due to its durability, long-term efficacy, and the ability to address concomitant structural issues, such as mitral valve abnormalities, during the same operative session.

2. Technical Specifications and Pathophysiology

The Mechanism of Obstruction

In HOCM, the primary pathophysiology involves:
* Asymmetric Septal Hypertrophy (ASH): Disproportionate thickening of the septum.
* Systolic Anterior Motion (SAM) of the Mitral Valve: The hypertrophied septum alters the geometry of the LVOT, creating a Venturi effect that pulls the mitral valve leaflets toward the septum during systole.
* Mitral-Septal Contact: This contact creates a physical barrier to blood flow, leading to increased LV pressures and secondary mitral regurgitation.

The Surgical Intervention

The procedure involves a median sternotomy and the institution of cardiopulmonary bypass. The surgeon approaches the LVOT through an aortotomy. The hallmark of the procedure is the extended Morrow myectomy, which involves the resection of a rectangular block of myocardial tissue from the septum, starting below the aortic valve and extending toward the apex, ensuring the removal of the specific area of obstruction.

3. Clinical Indications and Patient Selection

The decision to proceed with septal myectomy is driven by a combination of clinical symptoms and hemodynamic measurements.

Indications for Surgery

Contraindications

• Severe comorbidities making the patient ineligible for cardiopulmonary bypass.
• Non-obstructive HCM (where the obstruction is absent and symptoms are driven by diastolic dysfunction).
• End-stage heart failure with severe systolic dysfunction (where myectomy may worsen the condition).

4. Pre-Operative Preparation

Comprehensive pre-operative assessment is critical to ensure surgical success and minimize perioperative risk.

1. Imaging: Transthoracic and Transesophageal Echocardiography (TEE) to map the extent of hypertrophy and the anatomy of the mitral valve apparatus. Cardiac MRI is frequently used to assess myocardial fibrosis and precise septal thickness.
2. Cardiac Catheterization: Performed to rule out coronary artery disease (CAD), which may require concomitant bypass grafting.
3. Medication Management: Beta-blockers are typically continued until the morning of surgery. Antiplatelet agents should be managed according to institutional protocols to minimize bleeding risk.
4. Anesthesia Protocol: Focus on maintaining preload and avoiding excessive inotropic stimulation, which can exacerbate the obstruction prior to induction.

5. The Procedure: Step-by-Step

Phase I: Access and Bypass

• Median Sternotomy: Standard incision to access the heart.
• Cardiopulmonary Bypass (CPB): Standard cannulation of the aorta and right atrium. Cardioplegic arrest is induced to provide a bloodless field.

Phase II: The Myectomy

1. Aortotomy: An incision is made in the ascending aorta to expose the aortic valve.
2. Visualization: The aortic valve leaflets are retracted to visualize the LVOT.
3. Excision: The surgeon performs a precise incision into the hypertrophied septum. Using specialized instruments, a "trough" of muscle is removed. This removes the obstruction and prevents future mitral-septal contact.
4. Mitral Valve Inspection: If the mitral valve is intrinsically damaged (not just affected by SAM), it may be repaired or replaced during the same procedure.

Phase III: Completion

• Assessment: Saline irrigation and TEE are used to confirm the relief of the gradient and resolution of SAM.
• Closure: The aorta is closed, the heart is de-aired, and the patient is weaned from CPB.

6. Post-Operative Recovery Protocol

Recovery typically follows a standardized cardiovascular surgery pathway:

• Immediate Post-Op (0-24 hours): Intensive care monitoring for hemodynamic stability, arrhythmias (specifically heart block), and bleeding.
• Early Mobilization (Day 1-3): Gradual transition to oral intake and physical therapy to prevent pulmonary complications.
• Medication Adjustment: Patients are often weaned off high-dose beta-blockers or adjusted to maintenance doses. Anticoagulation is required only if a mechanical valve was implanted or if atrial fibrillation is present.
• Long-term Follow-up: Echocardiography is performed at 3-6 months to assess the degree of obstruction relief and mitral valve function.

7. Potential Complications

While highly successful, septal myectomy carries inherent risks associated with open-heart surgery:

• Iatrogenic Ventricular Septal Defect (VSD): The most feared complication, caused by over-resection of the septum.
• Complete Heart Block: Due to the proximity of the conduction system (Bundle of His) to the resection site, potentially requiring a permanent pacemaker.
• Aortic Insufficiency: Damage to the aortic valve leaflets during the approach.
• Arrhythmias: Atrial fibrillation is common in the post-operative period.
• Standard Surgical Risks: Infection, bleeding, stroke, and renal failure.

8. Alternative Treatments

When surgery is not feasible or desired, the following options are considered:

1. Alcohol Septal Ablation (ASA): A catheter-based procedure where ethanol is injected into the septal artery to induce a controlled infarct. It is less invasive but carries a higher risk of permanent pacemaker requirement and potential for residual obstruction.
2. Pharmacological Therapy: Primarily for symptom management; does not treat the underlying structural obstruction.
3. Cardiac Transplantation: Reserved for patients with end-stage, refractory HCM where myectomy is no longer a viable option due to extensive scarring or systolic failure.

9. Frequently Asked Questions (FAQ)

1. Is Septal Myectomy a permanent cure?

Yes, for the vast majority of patients, the removal of the hypertrophied muscle provides a long-term, durable relief of the obstruction.

2. How long will I be in the hospital?

The typical length of stay is 5 to 7 days, assuming an uncomplicated recovery.

3. What is the success rate?

In experienced centers, the success rate is >95%, with mortality rates often below 1%.

4. Will I need a pacemaker after surgery?

There is a 5-10% risk of requiring a permanent pacemaker due to damage to the heart's electrical conduction system during the procedure.

5. Can myectomy be performed minimally invasively?

While some centers offer robotic or small-incision approaches, the standard of care remains a median sternotomy to ensure full visualization of the septum.

6. When can I return to work?

Most patients return to light activities in 4-6 weeks and full activity within 3 months.

7. Does it fix the mitral valve?

Yes, in many cases, eliminating the obstruction (SAM) resolves the associated mitral regurgitation without the need for valve surgery.

8. How does it compare to Alcohol Septal Ablation?

Surgery generally offers more complete relief of the obstruction and lower long-term re-intervention rates compared to ablation.

9. Will I still need to take heart medication?

Many patients can reduce their medication burden, but some may still require beta-blockers for underlying heart rhythm management or blood pressure control.

10. Can this be done if I have coronary artery disease?

Yes, surgeons can perform a bypass (CABG) simultaneously with the myectomy.

10. Conclusion

Septal Myectomy remains the definitive intervention for HOCM. Its ability to surgically reshape the anatomy of the left ventricle provides patients with a significant improvement in quality of life and functional capacity. As with any major cardiac intervention, the importance of selecting a high-volume center with experienced cardiac surgeons and echocardiographers cannot be overstated. By adhering to rigorous pre-operative screening and meticulous intraoperative technique, the medical community continues to achieve excellent outcomes for this complex patient population.

Disclaimer: This guide is intended for informational and educational purposes only and does not constitute medical advice. Always consult with a board-certified cardiothoracic surgeon or cardiologist regarding specific clinical conditions and treatment options.